Sarepta (SRPT) calls active after FDA approves eteplirsen
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet to replace Verizon in the Dow Jones Industrial Average
- Cerebras Systems (CBRS) call put ratio 1 call to 1.1 puts into quarter results
- Micron Technology (MU) call put ratio 1.2 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
